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ImmunizationNovel vaccine development and production has given rise to a growing number of vaccines that can pre-
vent disease and save lives. In order to realize these health benefits, it is essential to ensure adequate
immunization financing to enable equitable access to vaccines for people in all communities. This anal-
ysis estimates the full immunization program costs, projected available financing, and resulting funding
gap for 94 low- and middle-income countries over five years (2016–2020). Vaccine program financing by
country governments, Gavi, and other development partners was forecasted for vaccine, supply chain,
and service delivery, based on an analysis of comprehensive multi-year plans together with a series of
scenario and sensitivity analyses.
Findings indicate that delivery of full vaccination programs across 94 countries would result in a total
funding gap of $7.6 billion (95% uncertainty range: $4.6–$11.8 billion) over 2016–2020, with the bulk
(98%) of the resources required for routine immunization programs. More than half (65%) of the resources
to meet this funding gap are required for service delivery at $5.0 billion ($2.7–$8.4 billion) with an addi-
tional $1.1 billion ($0.9–$2.7 billion) needed for vaccines and $1.5 billion ($1.1–$2.0 billion) for supply
chain. When viewed as a percentage of total projected costs, the funding gap represents 66% of projected
supply chain costs, 30% of service delivery costs, and 9% of vaccine costs. On average, this funding gap
corresponds to 0.2% of general government expenditures and 2.3% of government health expenditures.
These results suggest greater need for country and donor resource mobilization and funding allocation
for immunizations. Both service delivery and supply chain are important areas for further resource mobi-
lization. Further research on the impact of advances in service delivery technology and reductions in vac-
cine prices beyond this decade would be important for efficient investment decisions for immunization.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
The cost of national immunization programs (NIPs) is increasing
with the introduction of new vaccines and efforts to improve cov-
erage of existing vaccine schedules. A greater need to vaccinate
children in more remote and hard-to-reach areas also contributes
to the rising costs of immunization. The Global Vaccine Action Plan(GVAP) 2011–2020 – endorsed by the 194 member states of the
World Health Assembly in May 2012 – was created to facilitate
commitments to support immunization by presenting a roadmap
for strengthening NIPs through increased vaccination coverage
and introduction of new and underutilized vaccines. It outlines a
mission to improve health by extending, to 2020 and beyond, the
full benefits of immunization to all people. In order to achieve
GVAP goals, understanding the resources required for vaccination
programs and the projected gaps in financing is important to
ensure adequate and sustainable health investments in the world’s
poorest countries.
While governments share in the financing of vaccination
programs [1], achieving ambitious GVAP targets will require
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garnering these commitments lies in the difficulty of estimating
the resources required for NIPs. Estimating the level of financing
necessary to continue to reduce vaccine-preventable disease bur-
den worldwide is important to sustain and improve upon advances
made in immunization. Economic evidence is therefore essential to
enable governments and development partners to project funding
needs and commit resources toward vaccination.
This analysis augments the Decade of Vaccine Economics
(DOVE) project [2–4], extending prior efforts to examine financing
for immunization. Specifically, we explore six scenarios on the
impact of future cost and financing projections, link the latest cost
and financing requirements at a global scale, examine financing
requirements by cost components (vaccine, supply chain, service
delivery), and provide uncertainty ranges through sensitivity anal-
yses. By linking detailed vaccine program costs [2] with a range of
financing projections, this work provides an in-depth view of
immunization program resource requirements that reflect
dynamic realities such as economic growth and pricing policy
changes over time.2. Materials and methods
2.1. Analysis scope and approach
This analysis estimates the projected available financing and
resulting funding gap based on immunization program costs across
94 low- and middle-income countries (LMICs) over 5 years, 2016–
2020. This includes 73 countries supported by Gavi, the Vaccine
Alliance, and 21 countries not eligible for Gavi support. Gavi coun-
tries include 36 low-income countries, 17 countries above the
World Bank’s low-income threshold that received Gavi support,
and 20 countries that will graduate from receiving Gavi support
during 2016–2020 (see Appendix A for the full list of countries).
The model incorporates the following 18 vaccines currently in
national immunization programs in some LMICs: Bacillus
Calmette-Guérin (BCG), cholera, diphtheria-tetanus-pertussis
(DTP), DTP-hepatititis B-hib (pentavalent),2 hepatitis B birth dose,
human papillomavirus (HPV), inactivated polio (IPV), Japanese
encephalitis (JE), malaria, measles, measles-rubella (MR), measles-
mumps-rubella (MMR), meningococcal conjugate A (MenA), oral
polio (OPV), pneumococccal conjugate (PCV), rotavirus, typhoid,
and yellow fever (YF). These include 12 vaccines where Gavi sup-
ports partial or full financing to facilitate new vaccine introductions,
five other traditional vaccines, and a cholera stockpile. These vacci-
nes are delivered through a combination of channels, where 17 vac-
cines are provided through routine immunization programs and 8
vaccines through supplementary immunization activities (SIAs).3
The cholera vaccine is not routinely delivered but rather set aside
as stockpiles for cholera control and outbreak response.
We estimate vaccine program costs for three mutually-
exclusive components of routine immunization (vaccines, supply
chain, and service delivery) and two components of SIAs (vaccines
and operational support). Vaccine costswere defined as the costs of
procuring vaccines and related injection equipment and safety
boxes needed to safely administer vaccines. Supply chain costs
included the costs for immunization-specific and shared4 trans-
portation, storage, and cold-chain specific labor. Service delivery costs2 DTP-HepB-Hib refers to the diphtheria-tetanus-pertussis-hepatitis
B-Haemophilus influenzae type b vaccine, also known as pentavalent.
3 Supplementary immunization activities (SIAs) are defined through accelerated
disease control (ADC), elimination, or eradication initiatives (e.g., polio eradication
campaigns) that go beyond routine immunization.
4 Shared transportation refers to any transportation which is utilized for multiple
purposes, including but not limited to immunization.encompassed the costs of immunization-specific and shared5 per-
sonnel and non-personnel components including program manage-
ment, training, social mobilization, surveillance, and other
recurrent costs related to vaccination. Operational support for SIAs
included vaccine delivery and management of vaccination campaign
efforts. The categorization reflects classifications and definitions
used in previous vaccine program analyses [5–7]. Projected available
financing was estimated for each of these components.
Our method of analysis was developed with consideration of
the approaches and lessons learned from previous immunization
program costing exercises [5–8], and the availability and use of
country-level data. For example, data from national comprehensive
multi-year plans (cMYPs) provided the basis for estimates of
immunization costs and financing for the majority of Gavi coun-
tries. The cost and financing estimates in the cMYP are provided
by country teams using standardized guidelines developed by the
World Health Organization (WHO) [9]. Transparency of the model
design was also valued for continuous use and ability to update
future inputs. Table 1 presents the full scope of costing and financ-
ing analysis. All cost and financing projections are presented in
constant 2010 US dollars (US$2010).2.2. Costing of national immunization programs
The costing, financing, and funding gap analyses were con-
ducted concurrently across 18 vaccines over the decade, 2011–
2020. The costing analysis is presented in a companion piece [2].
Specifically, vaccine costs were primarily derived from Gavi, the
Pan American Health Organization (PAHO), and UNICEF price pro-
jections [10–15] in combination with doses from Gavi’s Adjusted
Demand Forecast version 9 (ADFv9, released spring 2014) [16].
Supply chain costs were modeled based on simulations of
country-specific models developed by the HERMES (Highly Exten-
sible Resource for Modeling Event-Driven Supply Chains) Logistics
Modeling Team [17–27]. Average and marginal service delivery
costs per dose and operational support for SIAs were obtained from
an analysis of cMYPs [28]. See Portnoy et al. for further details on
costing methods and results [2].2.3. Financing of national immunization programs
The financing analysis focuses on three funding sources: funds
from country governments, funds from Gavi and funds from ‘‘other
development partners” (ODP). Sources from ODP include multilat-
eral and bilateral donors, non-governmental organizations, foun-
dations, and private philanthropy organizations. Financing
approaches are summarized in Table 2.2.3.1. Government financing
In Gavi-supported countries, we estimated governments’ vac-
cine co-financing obligations articulated in the Gavi co-financing
policy based on the 2014 demand forecast (ADFv9) [16,29]. We
assumed that governments will meet these co-financing obliga-
tions for Gavi-supported vaccines [29]. For non-Gavi supported
vaccines, the baseline percentage of government financing for vac-
cines was obtained from cMYPs and applied to the total estimated
annual costs for those vaccines to estimate a plausible proportion
of vaccine financing by government. If a cMYP was not available
for a country, the percentage of government financing of routine
vaccines was taken from the WHO/UNICEF Joint Reporting Form
(JRF), and was projected forward until 2020 using a five-year5 Shared personnel are defined as resources that are not specific to immunization
and are used by different programs or activities in the health sector.
Table 1
Scope of analysis by delivery mechanism, components, vaccines, and sources.a
Components Vaccines with Gavi support (Financed by Gavi,
government & other development partners)
Vaccines without Gavi support (Financed by
government & other development partners)
Routine
Vaccine
 Vaccine incl. freight
 Injection equipment and safety boxes
DTP-HepB-Hib, HPV, IPV, JE, Malaria,
Measles 2nd, MR, MenA, PCV, Rotavirus, Typhoid, YF
BCG, DTP, HepB birth, Measles 1st, MMR, OPV
Supply chain
 Immunization-specific transportation
 Shared transportation
 Storage
 Labor
Service delivery
 Immunization-specific personnel
 Shared personnel
 Non-personnel incl. training, surveillance,
program management, social mobilization
SIA
Vaccine
 Vaccine incl. freight
 Injection equipment and safety boxes
JE, Malaria, Measles, MR, MenA, Typhoid, YF MMR, OPV
Operational support
 Personnel
 Other operational costs incl. training, transporta-
tion, and social mobilization
a The analysis also includes a cholera stockpile, additional support for Gavi supported vaccine stockpiles, and advanced market commitments (AMC) for PCV.
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tries in the analysis.
In response to the anticipated introduction of the inactivated
polio vaccine (IPV) in these 94 countries as part of the polio erad-
ication initiative [31,32], governments in all 94 countries were
assumed to cover a share of IPV routine vaccine financing accord-
ing to the ratio of the price of the oral polio vaccine (OPV) relative
to the price of IPV.
Proportions of government financing for supply chain and ser-
vice delivery were obtained from the most recently validated year
in a cMYP (called the ‘‘baseline year” in the cMYP) and applied to
the same year’s estimates of supply chain and service delivery
costs. In the 31 countries without cMYP data, population-
weighted government financing ratios for supply chain and service
delivery were estimated from a cMYP analysis of data for 63 coun-
tries. Government financing of supply chain and service delivery
was projected to grow from the baseline year at the same rate as
real gross domestic product (GDP) growth in the base case esti-
mate. The cost of shared personnel was assumed to be 100%
government-financed in the analysis; thus by default there is no
funding gap estimated for shared personnel as we expect govern-
ments to fully fund human resources not specific to immunization.
For SIA vaccines without Gavi support, specifically the measles-
mumps-rubella (MMR) vaccine and OPV, percentage of govern-
ment financing relative to resource requirements was abstracted
from cMYPs for the most recently validated year. This percentage
was used to estimate government SIA vaccine and operational sup-
port financing across the decade. Specifically, countries with a
funding gap in their baseline year of cMYP maintained the percent-
age gap in projected years. In the 31 countries without a cMYP, SIA
government financing per capita metrics were obtained from 63
countries with cMYP data to project SIA government support. A full
list of countries and their cMYP availability can be found in Appen-
dix A. Metrics were population-weighted and vaccine-specific. For
the 31 countries, no funding gap was projected for the SIA vaccine
component due to a lack of data on any existing or future funding
shortages.2.3.2. Gavi financing
We modeled financing amounts committed by Gavi based on
routine and supplementary vaccine co-financing obligations
according to Gavi’s demand forecast (ADFv9) between 2016 and
2020 [16]. These obligations were assumed to be met in full by
Gavi over the decade. Gavi entirely finances all SIA vaccine doses
for Gavi-supported vaccines in the 73 Gavi countries.
Gavi’s health systems strengthening (HSS) disbursements for
2011–2014 were used to project 2016–2020 disbursements. These
disbursements were projected according to the ceiling set by Gavi
for HSS support in each country relying on an assumption that the
annual proportion of the support ceiling would be uniform until
2020 [33–35]. In addition, Gavi support for vaccine introduction
was calculated by multiplying the vaccine introduction subsidy –
US$0.80 for child vaccines and $2.40 for human papillomavirus
(HPV) vaccine – per target person in the year of introduction for
each vaccine [36]. Total Gavi non-vaccine support was separated
into supply chain and service delivery components by disaggregat-
ing HSS proposal support according to the category of the approved
Gavi grant. This analysis conducted by the Gavi Secretariat esti-
mated 21% of HSS spending was going to supply chain and 79%
to service delivery for all Gavi-approved HSS grants. Gavi’s opera-
tional support for SIAs was estimated by multiplying Gavi’s opera-
tional subsidy of $0.65 per target person by the target population
of each Gavi-supported SIA campaign [36].
2.3.3. Other Development Partner (ODP) financing
For 63 countries with cMYP data, we obtained the baseline year
share of ODP financing relative to total resource requirements for
each cost component – routine vaccine, routine supply chain, rou-
tine service delivery, SIA vaccine, and SIA operational support. For
31 countries without cMYP data, the percentage of ODP financing
for each cost component was estimated based on an analysis of
cMYP baseline year data abstracting population-weighted ODP
financing ratios for supply chain and service delivery.
For routine vaccine, SIA vaccine, and SIA operational support
components, the share of ODP financing was held constant across
Table 2
Summary of financing estimation and projection methods.
Government,
Gavi, or ODP
Routine
or SIA
Vaccines Country
groupingsa
Component Base financing Projection method Implications on the funding
gap
Government
financing
Routine Gavi
supported
routine
vaccines
Gavi
countries
(73)
Vaccine Gavi co-financing
obligations specified by
Gavi policy and ADFv9b
Dependent on co-financing
obligations specified in ADFv9
All government
commitments forecasted by
the ADFv9 were projected
to be met in full
Routine
vaccines
not
supported
by Gavi
Gavi
countries
with cMYP
data (63)
Percentage of government
financing from cMYP
baseline year data
Constant percentage applied to
estimated costs for projection
years
Gavi
supported
routine
vaccines
Non-Gavi
countries
(21)
Percentage of government
financing from JRF data
Five-year rolling average Baseline year levels of
government financing will
remain constant over time
relative to projected costs
Routine
vaccines
not
supported
by Gavi
Countries
without
cMYP data
(31)
All routine
vaccines
Gavi
countries
with cMYP
data (63)
Supply chain
and service
deliveryc
Percentage of government
financing from cMYP
baseline year data
IMF projections of real GDP growth Government immunization
budgets will grow at the
same rate as GHE, which is
assumed to grow at real
GDP ratesCountries
without
cMYP data
(31)
Population-weighted
government financing
ratios estimated from
cMYP baseline year data
SIA All SIA
vaccines
Gavi
countries
with cMYP
data (63)
Vaccine &
Operational
Percentage of government
financing from cMYP
baseline year data
Constant percentage applied to
estimated costs for projection
years
Only countries with a
funding gap in their
baseline year cMYP data
have an estimated funding
gap for the SIA vaccine &
operational components
Countries
without
cMYP data
(31)
Vaccine &
Operational
Population-weighted
government financing
ratios estimated from
cMYP baseline year data
There is no estimated
funding gap for the SIA
vaccine & operational
components
Gavi
financing
Routine Gavi
supported
routine
vaccines
Gavi
countries
(73)
Vaccine Gavi co-financing
obligations specified by
Gavi policy and ADFv9
Dependent on co-financing
obligations specified in ADFv9
All Gavi commitments
forecasted by the ADFv9
were projected to be met in
full
Vaccine
introduction
support
Gavi vaccine introduction
support subsidy ($0.80 for
infant vaccines and $2.40
for HPV)
Calculated by multiplying the
vaccine introduction subsidy per
target person in year of
introduction for each Gavi-
supported vaccine
Gavi will provide funding in
line with its vaccine
introduction grant policy
Supply chain
and service
delivery
Gavi health systems
strengthening (HSS)
disbursements
Projected according to ceilings set
by Gavi for HSS support
Gavi HSS support will not
exceed ceiling levels across
the decade
SIA Gavi
supported
SIA
vaccines
Vaccine Gavi co-financing
obligations specified by
Gavi policy and ADFv9
Dependent on co-financing
obligations specified in ADFv9
Gavi entirely finances all SIA
vaccines doses for Gavi-
supported vaccines in Gavi
countries
Operational Gavi operational support
subsidy ($0.65 per target
person)
Calculated by multiplying the
operational support subsidy per
target person by target population
of each Gavi-supported campaign
Gavi will provide funding in
line with its operational
support for campaigns
policy
ODP
financing
Routine All routine
vaccines
Gavi
countries
with cMYP
data (63)
Vaccine Percentage of ODP
financing from cMYP
baseline year data
Percentage applied to estimated
costs for projection years
Baseline year levels of ODP
financing will remain
constant over time relative
to projected costs
Supply chain
and service
delivery
IMF projections of real GDP growth ODP immunization support
will grow at least at the
same rate as economic
growth
Countries
without
cMYP data
(31)
Vaccine Population-weighted ODP
financing ratios estimated
from cMYP baseline year
data
Percentage applied to estimated
costs for projection years
There is no estimated
funding gap for the routine
vaccine component for
countries without cMYP
data
Supply chain
and service
delivery
IMF projections of real GDP growth
(continued on next page)
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Table 2 (continued)
Government,
Gavi, or ODP
Routine
or SIA
Vaccines Country
groupingsa
Component Base financing Projection method Implications on the funding
gap
SIA All SIA
vaccines
Gavi
countries
with cMYP
data (63)
Vaccine &
Operational
Percentage of ODP
financing from cMYP
baseline year data
Percentage applied to estimated
costs for projection years
Only countries with a
funding gap in their
baseline year cMYP data
have an estimated funding
gap for the SIA vaccine &
operational components
Countries
without
cMYP data
(31)
Vaccine &
Operational
Population-weighted ODP
financing ratios estimated
from cMYP baseline year
data
There is no estimated
funding gap for the SIA
vaccine & operational
components
Abbreviations: cMYP, comprehensive multi-year plan; GDP, gross domestic product; HPV, human papillomavirus vaccine; HSS, health systems strengthening; IMF, Inter-
national Monetary Fund; JRF, WHO-UNICEF Joint Reporting Form; MMR, measles-mumps-rubella vaccine; ODP, other development partners; OPV, oral polio vaccine; SIA,
supplementary immunization activities.
a See Appendix A for country groupings. Projected Gavi support for vaccines was dependent on country-specific forecasts of vaccine introduction and annual anticipated
Gavi status. Gavi vaccines include the following: DTP-HepB-Hib (Pentavalent), HPV, IPV, JE, malaria, measles 2nd dose and measles SIAs, MR, MenA, PCV, rotavirus, typhoid,
YF, and cholera (stockpile). Vaccines without Gavi support include BCG, DTP, HepB birth dose, measles 1st dose, MMR, and OPV.
b As introduction of inactivated polio vaccine (IPV) is anticipated in all 94 countries as part of the polio eradication plan, a separate assumption was developed for the
financing of the routine IPV rollout. Governments in all 94 countries are assumed to cover a share of IPV routine vaccine financing according to the ratio of the OPV vaccine
price relative to the IPV vaccine price. The remaining price differential is included in the funding gap estimate.
c The cost of shared personnel is assumed to be 100% financed by all financing sources (i.e., by default there is no funding gap for shared personnel). Therefore, all shared
personnel costs that are not met by Gavi and ODP financing are projected to be funded fully by government financing.
6 DTP3 includes three doses of diphtheria, tetanus and pertussis vaccines and is
ften used as a standard measure for the strength of a country’s immunization
stem.
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service delivery financing, ODP financing from the baseline year
was projected to grow at the rate of real GDP growth for each coun-
try to account for inflation.
2.4. Funding gap of national immunization programs
The funding gap was obtained by taking the difference between
estimated costs of providing vaccines and the financing projected
to be available for the period from 2016 to 2020. This analysis pre-
sents the funding gap by financing source (country governments,
Gavi, and ODP) as well as by cost component categories (vaccine,
supply chain, and service delivery).
2.5. Scenario analyses
A series of scenario analyses were carried out to examine the
impact of various cost and financing projections on an estimated
funding gap. Specifically, we modeled six funding gap scenarios
involving three costing scenarios and three financing scenarios.
Three costing scenarios were developed to modify base case
cost estimates using the following methods:
1. Vaccine price reduction scenario: In this scenario, all 21 non-
Gavi countries were hypothetically assumed to be able to access
vaccines at Gavi-subsidized prices for all Gavi vaccines [10].
This demonstrates the impact on costs if additional middle-
income countries were able to access the same vaccine prices
as Gavi countries.
2. 90% coverage scenario: This scenario modeled the cost implica-
tions of reaching the GVAP goal for all countries to achieve 90%
coverage by 2020 for vaccines included in their NIPs. In order to
model this coverage increase, 2012 coverage levels were used to
project coverage linearly for the 2016–2020 time period to even-
tually reach 90% coverage by 2020 for all vaccines that had been
introduced prior to 2017.When the Gavi Strategic Demand Fore-
cast version 9 (SDFv9) coverage for any country in any year was
greater than modeled coverage for the 90% scenario, the SDFv9
coverage level was used. SDFv9 coverage was maintained for
all routine vaccines introduced during or after 2017 [37,38].
3. Marginal service delivery cost scale-up scenario: This scenario
examined the additional costs of reaching hard to reach
populations. Specifically, we applied a proportional increase(approximately 126%) to marginal service delivery costs for
countries with DTP36 coverage at or above 90% based on an esti-
mate of cost per health center visit [39].
Three additional financing scenarios were modeled which
altered base case financing projections using various methods:
4. Historic GDP elasticity of government financing: This scenario
considered an optimistic government financing growth using
estimates of the change in government health expenditures
(GHE) relative to changes in GDP to predict vaccine financing
trends in countries as their economies grow. All GHE and GDP
data were obtained from the World Bank [40]. Elasticity was
defined as the annual proportional change in GHE, divided by
the same annual proportional change in GDP, estimated from
2009 to 2013. Results were aggregated by World Bank income
group.
5. Projected government expenditures as a percentage of GDP
financing: This scenario grew government financing based on
government expenditure (GE) projections rather than real
GDP growth [40].
6. Historic GDP elasticity of ODA financing: In this analysis, we
accounted for change in ODP financing by examining changes
to financing of other development assistance (ODA) grouped
by WHO region [40]. The analysis estimated historic ODA elas-
ticity of GDP to predict how ODP may decrease financing as
recipient countries’ economies grow. Elasticity was defined as
the annual proportional change in ODA, divided by the same
annual proportional change in GDP, 2009–2013. Results were
aggregated by WHO country regions.
2.6. Sensitivity analysis
Sensitivity analysis was carried out varying seven key costing
inputs and one financing input in model simulations to construct
the 95% uncertainty ranges around baseline estimates. Specifically,
we performed a probabilistic sensitivity analysis using the Monte
Carlo method, building distributions around key model parameters
including total doses, vaccine prices, slopes and extrapolations ofo
sy
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cost per dose for service delivery, and operational cost per dose for
SIA for costing and real GDP growth for financing. For each param-
eter, random draws were taken from specified distributions 10,000
times. Non-cost values were given a beta distribution, while cost
values used gamma distributions in order to represent the skew
of observed costing data. Costing parameters were ranged between
half and double the base estimate to examine the effect of each
variable; real GDP growth was varied from 91% to 109% capturing
two standard deviations across all countries and years of data. This
analysis was implemented using the latest version of the Palisade’s
@RISK software.3. Results
3.1. Base case
In the remaining five years of this decade (2016–2020), we
observe a base case funding gap of $7.6 billion (95% uncertainty
range: $4.6–$11.8 billion), resulting from the difference between
an estimated US$35.7 billion in NIP costs and US$28.1 billion in
projected available financing. This funding gap consisted of $6.9
billion across 73 Gavi countries and $0.7 billion among the 21
non-Gavi countries. Service delivery to support immunization pro-
grams, including costs for program management, training, social
mobilization, and surveillance accounted for the largest proportion
of the expected costs ($14.0 billion) and contributed 65% or US$5.0
billion ($2.7–$8.4 billion) to the funding gap. A funding gap of US
$1.1 billion for vaccines ($0.9–$2.7 billion) and $1.5 billion for sup-
ply chain ($1.1–$2.0 billion) comprised 9% and 66% of estimatedTable 3
Estimated costs, projected financing, and resulting funding gap for 2016–2020 (US
$2010 billions).
Component Costs Financing Funding gap
Routine $30.9 $23.4 $7.5
Vaccine $12.3 $11.2 $1.1
Supply chain $2.3 $0.8 $1.5
Service delivery $16.3 $11.4 $4.9
SIA $4.8 $4.6 $0.1
Vaccine $2.1 $2.0 <$0.1
Operational support $2.6 $2.6 <$0.1
Total $35.7 $28.1 $7.6
Fig. 1. Projected available costs, financing andcosts respectively for those components. Table 3 shows the cost,
financing, and funding gap over 2016–2020 by component. While
service delivery is the main driver of the funding gap in absolute
dollar value, the supply chain component faces the greatest gap
in funding as a proportion of costs.
The base case financing highlights the important role of govern-
ment financing with $16.2 billion contributed by national govern-
ments. External donors continue to play a supportive role, with
$9.9 billion provided by Gavi and $1.9 billion by ODP between
the years 2016–2020. Fig. 1 presents the total projected available
financing for immunization programs by funding source across
the years.
3.2. Scenario and sensitivity analyses
Among the modeled scenarios, the funding gap was found to be
smallest for the vaccine price reduction scenario ($6.3 billion) and
highest for the 90% coverage scenario ($9.2 billion). Scaling up
marginal delivery costs to reach hard-to-reach populations had
the next largest effect, increasing the funding gap by 13% ($1.0 bil-
lion). If non-Gavi countries were able to access Gavi vaccine prices
the funding gap was reduced by 19% ($1.4 billion) compared to the
base case. The costing scenarios had a greater effect on the funding
gap ranging the final funding gap estimate by 81–119% ($6.25–$9.
16 billion) compared to financing scenarios ranging the funding
gap by 96–101% ($7.39–$7.68 billion). Table 4 presents the results
across examined scenarios.
The three financing scenarios had little effect on the base fund-
ing gap estimate. Specifically, changing the projections from real
GDP growth to government health expenditure elasticity of GDP
closed the funding gap by nearly four percent to $7.4 billion over
2016–2020. Growing government financing based on government
expenditure projections or altering ODP growth using GDP elastic-
ity of ODA financing had a minimal effect on the funding gap.
Sensitivity analysis around base case parameter values revealed
that the service delivery marginal cost per dose is the biggest dri-
ver of the base funding gap estimate (24% lower to 41% higher), fol-
lowed by projected doses (29% lower to 33% higher), service
delivery average cost per dose (7% lower to 15% higher), and vac-
cine prices (8% lower to 13% higher). Assumptions around real
GDP growth for financing projections, SIA operational cost per
dose, and supply chain cost extrapolations were less influential
on the funding gap (see Appendix B for a tornado diagram).funding gap by funding source by year.
Table 4
Funding gap scenario results, 2016–2020 (US$ billions).
Scenario # Scenarios Total costs Total financing Total funding gap % Change in funding gap
from base case
Base case 35.69 28.06 7.63 N/A
Costing Scenarios (using base financing)
1 Price Reduction Scenario Costs 34.26 28.06 6.20 18.76%
2 90% Coverage Scenario Costs 37.46 28.06 9.41 23.22%
3 Marginal Service Delivery Cost Scale-Up 36.71 28.06 8.65 13.32%
Financing Scenarios (using base costs)
4 Historic GDP Elasticity of Government Financing 35.69 28.30 7.39 3.79%
5 Projected Government Expenditures as % of GDP Financing 35.69 28.01 7.68 0.01%
6 Historic GDP Elasticity of ODA Financing 35.69 28.02 7.67 0.01%
Table 5
Comparison to Gandhi et al. [6] Findings, 2016–2020 (US$2010 billions).
Gandhi et al.a Our analysis
Total costs 32.9 35.7
Total financing 18.7 28.1
Total funding gap 14.2 7.6
a Key methodological differences with the Gandhi et al. analysis include the
following. Gandhi et al. uses: (1) dose projections from 2011 Gavi Adjusted Demand
Forecast (version 4) rather than from 2014 (version 9); (2) constant vaccine prices
across the decades rather than prices that are projected to decrease; (3) a global
deflator for conversion to US$2010 rather than local inflation based on consumer
price indices (CPI); (4) different cMYP data and methods used to derive projected
available financing (see Table 1 for current analysis and Table 3 in Gandhi et al.); (5)
earlier values of Gavi support subsidies; and (6) financing metrics based on Gavi co-
financing groupings (see Table 3 in Gandhi et al.).
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Despite the commitments from government, Gavi, and other
development partners to achieve global immunization goals, we
estimate a $7.6 billion (uncertainty range: $4.6–$11.8 billion) base
case funding gap from 2016 to 2020 for NIPs. This funding gap
amounts to approximately 0.2% of general government expendi-
tures on average across 94 countries. Taking government health
expenditures as a percentage of government expenditures from
2012–2014 and applying it to 2016–2020, the funding gap repre-
sents 2.3% of government health expenditures on average across
94 countries. This analysis conducted a series of scenario analyses
to examine the impact of projections on financing and funding gap
for NIPs to reach GVAP targets in the Decade of Vaccines. We found
that the financing scenarios, which optimistically grew available
government financing or pessimistically grew ODP financing, did
not have a large impact on closing the funding gap. This suggests
that precision of costing data may be more essential than the
financing data to estimate the funding gap. It also speaks to the
need for changes in immunization program investment beyond
the level that was projected at the beginning of the decade to
address this funding gap for immunizations.
Of note, the main driver of the funding gap stems from the ser-
vice delivery component, which highlights the critical need for
health systems strengthening efforts to support immunization cov-
erage goals. Although the overall projected cost was smallest for
supply chains ($2.3 billion from 2016 to 2020), this component
was underfunded, covering 34% of total costs. Note that this anal-
ysis was done prior to the launch of Gavi’s Cold Chain Equipment
(CCE) facility which will provide up to $50 million in support. As
for sources of financing, the majority of available financing (58%)
was projected to come from country governments. This finding is
similar to that found in a recent multi-country study of routine
immunization financing (EPIC) and analysis of cMYP data
[1,41,42]. While this supports the GVAP principles to promote
country ownership in national immunization programs, additional
government funds may be necessary both to reduce the funding
gap and reliance on support from Gavi and other development
partners [43].
In 2015, Gavi replenished its commitment to deliver vaccines to
millions of the world’s poorest children with a $7.5 billion pledge
for 2016–2020 from its partners, including international institu-
tions, donor organizations, country governments, and the pharma-
ceutical industry. These new pledges support Gavi’s financing
projected in this analysis and are a part of the $9.9 billion that Gavi
is projected to contribute towards immunization over the next five
years. This contribution from Gavi, providing 35.4% of projected
total funding, is an essential piece of the financial support structure
for low- and lower-middle income countries that will enable coun-
tries to immunize an additional 300 million children and avert 5–6
million premature deaths [44]. Since this analysis, Gavi and the
Global Polio Eradication Initiative (GPEI) have also committed tosupporting a one-time cash grant to cover additional costs of intro-
ducing the IPV vaccine for Gavi countries. If polio is eradicated
between 2016 and 2020, there may also be opportunities to reallo-
cate some funding to meet the funding gap.
Our analysis updates an earlier estimate conducted by Gandhi
et al. (2013). Our analysis projected financing from governments,
Gavi, and other development partners to be $28.1 billion, greater
than in the previous estimate by approximately $9.4 billion
between 2016 and 2020 [6]. This is due to a distinct methodolog-
ical approach based on proportional rather than per capita alloca-
tions. As a result, our analysis estimates a smaller funding gap of
$7.6 billion compared to $14.2 in the previous analysis. This could
be due to use of more up-to-date data supporting actual increases
in financing in the decade resulting in a smaller gap. While the pro-
jection methods for financing differ between the two analyses, the
growth in the financing estimates is also due to a combination of
greater immunization coverage scale-up and increasing number
of vaccine introductions across the decade in the latest Gavi
demand forecast [16] compared to the version used by Gandhi
et al. in their analysis [45]. Financing projections will grow over
time as hard-to-reach populations may become more costly to
access and new vaccine introductions demand greater commit-
ment. A comparison to the previous analysis by Gandhi et al.
(2013) can be found in Table 5.
There are a number of limitations in this analysis that are
important to note. Specifically, the costs, financing, and funding
gap estimates presented are subject to uncertainties regarding
changes to future vaccine prices, doses demanded and procured,
and financial flows. While we tried to use a series of scenario
and sensitivity analyses to understand the impact of current data
and assumptions, additional scenarios, budgetary data, and empir-
ical evidence could be examined to look further into these projec-
tions. For example, the uncertainty around Gavi’s demand forecast
is important to note as vaccine recommendations and policies
around new vaccines are in a state of rapid change. In addition,
model inputs such as vaccine prices, demand forecasts, govern-
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ings are constantly refined by Gavi and others. The uncertainty
ranges could also be improved with additional data to reflect dif-
ferent uncertainties of inputs. While our results used the latest
data sources at the time of analysis, we have built the model such
that these estimates could be updated in future analyses.
The quality and availability of existing data is another limiting
factor in this analysis, particularly our reliance on cMYP data.
While cMYP data currently are the best sources for costing and
financing of immunizations across LMICs, they are compiled for
Gavi applications with potential inconsistencies in cost definitions
and calculations, and weak validation methods. In addition, cMYP
data were only available in two-thirds of countries receiving Gavi
support for immunization, which were then used to estimate costs
and financing for the remaining countries. Since some countries
without cMYPs are higher-income countries, the base case may
be an underestimation of costs and government financing and an
overestimation of contributions of other development partners,
adding to uncertainties around the results. However, comparisons
with latest evidence on vaccine assistance across all LMICs suggest
that our projection of contributions by other development partners
may be conservative [43]. Even with the variations in data quality,
cMYPs are currently the most detailed source of continuously
updated cost and financing estimates of NIPs at a country level.
This analysis informs the greater financial support necessary to
support vaccine programs across 94 countries to achieve the GVAP
vision to make the benefits of immunization available to all. The
estimated funding gap, regardless of scenarios, suggests the need
for additional country and donor commitments to mobilize and
effectively allocate resources, especially for the service delivery
component of national immunization programs and relatively
underfunded country supply chains. Further research on the influ-
ences that investments in technological changes and price reduc-
tions have on reducing the funding gap should be conducted to
inform governments and other development partners about the
most efficient use of future resources.Acknowledgements
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